Stay updated on Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A consolidated Locations section now lists California, Illinois, Indiana, and Virginia, replacing the former separate California Locations, Illinois Locations, Indiana Locations, and Virginia Locations subsections; the HHS Vulnerability Disclosure link was removed.
    Difference
    0.5%
    Check dated 2025-12-23T10:14:42.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    Minor site-wide update applied: Revision v3.3.2 replaces v3.3.1; no changes to the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T17:52:37.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The page shows a new Revision: v3.3.1 and removal of Revision: v3.2.0, indicating a minor backend or metadata update without changing the trial details presented. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-24T14:45:40.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The page removed a general government funding status notice that previously appeared at the top, leaving the study details unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-17T06:56:37.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    The page content remains unchanged: the study overview, design, inclusion/exclusion criteria, and outcomes are as previously presented.
    Difference
    0.4%
    Check dated 2025-11-03T01:20:56.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    Key updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.
    Difference
    2%
    Check dated 2025-10-05T10:07:44.000Z thumbnail image

Stay in the know with updates to Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.